Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis.

Literature DB >> 31427294

Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis.

François Barde¹, Eliane Billaud², Lauriane Goldwirt³, Catherine Horodyckid⁴, Vincent Jullien², Fanny Lanternier^1,5, Philippe Lesprit⁶, Lucie Limousin⁷, Jérémie F Cohen¹, Olivier Lortholary^8,5.

Abstract

Posaconazole diffusion has been documented in various organs, which contrasts with the scarce data available for the human central nervous system (CNS). We analyzed posaconazole concentrations in plasma and multiple CNS specimens taken from a patient who received posaconazole because of cerebral phaeohyphomycosis. Low posaconazole concentrations were obtained in CNS specimens, with sample-to-plasma ratios between 5% and 22%. This case highlights the role of neurosurgery during cerebral phaeohyphomycoses, even those caused by posaconazole-susceptible black fungi.

Entities: Chemical Disease Species

Keywords: Rhinocladiella mackenziei; antifungal therapy; cerebral phaeohyphomycosis; invasive fungal infections; plasma drug levels; therapeutic drug monitoring

Mesh：

Substances：

Year: 2019 PMID： 31427294 PMCID： PMC6811437 DOI： 10.1128/AAC.01184-19

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors: Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal: N Engl J Med Date: 2007-01-25 Impact factor: 91.245

2. Posaconazole concentrations in the central nervous system.

Authors: Maria J G T Rüping; Nadine Albermann; Friedrich Ebinger; Irene Burckhardt; Claudia Beisel; Carsten Müller; Jörg J Vehreschild; Matthias Kochanek; Gerd Fätkenheuer; Christopher Bangard; Andrew J Ullmann; Wolfgang Herr; Karin Kolbe; Michael Hallek; Oliver A Cornely
Journal: J Antimicrob Chemother Date: 2008-09-28 Impact factor: 5.790

Review 3. Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system.

Authors: Katharine E Stott; William Hope
Journal: Expert Opin Drug Metab Toxicol Date: 2018-07-09 Impact factor: 4.481

4. Cerebral phaeohyphomycosis caused by Rhinocladiella mackenziei in a woman native to Afghanistan.

Authors: Alejandro Cristini; Dea Garcia-Hermoso; Marie Celard; Gilles Albrand; Olivier Lortholary
Journal: J Clin Microbiol Date: 2010-06-30 Impact factor: 5.948

5. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors: Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal: Clin Infect Dis Date: 2006-11-28 Impact factor: 9.079

Low Central Nervous System Posaconazole Concentrations during Cerebral Phaeohyphomycosis.

1. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

2. Posaconazole concentrations in the central nervous system.

Review 3. Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system.

4. Cerebral phaeohyphomycosis caused by Rhinocladiella mackenziei in a woman native to Afghanistan.

5. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

6. Activity of posaconazole in the treatment of central nervous system fungal infections.

7. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole.

8. Posaconazole concentrations in human tissues after allogeneic stem cell transplantation.

9. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier.

Review 10. Tissue penetration of antifungal agents.

1. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.

2. COVID-19-Associated Mucormycosis: What Neurologists Should Know?